Skip to content
AnalystLens

Neurocrine Biosciences Annual Report (Amendment), Year Ended Dec 31, 2015

Filing Date
Filed April 29, 2016
Period End
December 31, 2015
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K/A filed April 29, 2016. Cited figures are marked; the original filing is the authoritative source.

This Amendment No. 1 to Neurocrine Biosciences, Inc.'s Form 10-K for the fiscal year ended December 31, 2015 does not contain financial statements.

It restates Part III, Items 10 through 14, and adds new Section 302 and 906 certifications under Item 15. The company says it filed this amendment because it did not expect its definitive proxy statement for the election of directors to be filed within 120 days after fiscal year-end, so the Part III information incorporated by reference from the proxy could not be relied on. The original Form 10-K was filed February 11, 2016.

The filing describes Neurocrine's two lead late-stage programs: elagolix, a gonadotropin-releasing hormone antagonist for women's health partnered with AbbVie Inc., and valbenazine, a VMAT2 inhibitor for movement disorders that the company intends to commercialize in part. The compensation discussion states that the company met its 2015 corporate goals at the 100%a level, citing positive Phase III tardive dyskinesia results, a successful Tourette syndrome Phase Ib study, an out-license of valbenazine in Japan and certain other Asian countries, and a public stock offering. It also states that the 2015 share price rose by approximately 250%.

Ernst & Young LLP fees totaled $625,798b for 2015, compared with $598,293 for 2014. Ownership data as of March 15, 2016 show 86,571,700 common shares outstanding. The largest holders reported are FMR LLC at 14.9%, T.

Rowe Price Associates at 11.1%c, and BlackRock at 8.1%. All current executive officers and directors as a group hold 4.8%.

Chief Executive Officer Kevin C. Gorman's 2015 total compensation was $5,011,967d in the Summary Compensation Table.

Key Highlights

  1. Filed as Amendment No. 1 to restate Part III (Items 10-14) of the original 10-K, which was filed February 11, 2016, because the proxy statement was not expected before April 29, 2016.
  2. Two lead late-stage programs: elagolix (partnered with AbbVie Inc.) for women's health and valbenazine for movement disorders.
  3. Company reports it met its 2015 corporate goals at the 100% level, including positive Phase III tardive dyskinesia results and an out-license of valbenazine in Japan and certain other Asian countries.
  4. Ernst & Young LLP fees were $625,798 for 2015, versus $598,293 for 2014, including $575,798 in audit fees.
  5. 86,571,700 common shares outstanding as of March 15, 2016; FMR LLC (14.9%), T. Rowe Price Associates (11.1%) and BlackRock (8.1%) are the largest reported holders.
  6. CEO Kevin C. Gorman's 2015 total compensation was $5,011,967, with a $345,000 cash incentive at 100% goal achievement.
  7. Company stock price rose approximately 250% in 2015, per the compensation discussion.

Financial Statements

FY2015 against FY2014

Line itemFY2015FY2014Change
Revenue$19.77M$0—
Cost of Revenue$0——
Gross Profit$19.77M——
R&D Expenses$81.49M$46.42M+75.5%
SG&A Expenses$32.48M——
Operating Expenses$113.97M$64.41M+76.9%
Operating Income-$94.20M-$64.41M−46.3%
Interest Expense$0——
Net Income-$88.93M-$60.54M−46.9%
EPS (Basic)$-1.05$-0.81−29.6%
EPS (Diluted)$-1.05$-0.81−29.6%
Shares Outstanding (Basic)84.50M74.58M+13.3%
Shares Outstanding (Diluted)84.50M74.58M+13.3%

Frequently Asked Questions

  1. Why was this 10-K/A filed?

    The company filed Amendment No. 1 to include Part III information (directors, executive compensation, ownership, related transactions, and accountant fees) that the original Form 10-K had omitted under General Instruction G(3). The company did not expect its definitive proxy statement for the election of directors to be filed by April 29, 2016, which is 120 days after fiscal year-end.

  2. What were the company's 2015 corporate performance results?

    The compensation committee determined that the company met its 2015 corporate goals at the 100% level. Cited achievements include successful Phase III results for valbenazine in tardive dyskinesia, a successful Tourette syndrome Phase Ib study, completing enrollment for the Kinect 4 study, and a public offering of common stock. The filing also notes that AbbVie's partnered elagolix program reported positive Phase III endometriosis results.

  3. How much was the CEO paid in 2015?

    The Summary Compensation Table reports total 2015 compensation of $5,011,967 for Kevin C. Gorman, Ph.D., President and CEO. This included a salary of $575,000, a bonus of $345,000, option awards of $3,225,000, stock awards of $824,750 and other compensation of $42,217.

  4. Who are the largest stockholders?

    Based on Schedule 13G filings, FMR LLC beneficially owns 12,929,451 shares (14.9%), T. Rowe Price Associates, Inc. owns 9,633,687 shares (11.1%), BlackRock, Inc. owns 7,046,711 shares (8.1%), The Vanguard Group owns 5,938,031 shares (6.9%), and OrbiMed Advisors LLC owns 5,029,948 shares (5.8%). All current executive officers and directors as a group beneficially own 4.8%.

  5. What was the audit firm paid in 2015?

    Ernst & Young LLP billed total fees of $625,798 for 2015, consisting of $575,798 in audit fees and $50,000 in tax fees. The 2014 total was $598,293. The Audit Committee pre-approved all services and concluded that the non-audit services were compatible with the firm's independence.